Cargando…

Human Papilloma Virus vaccine and cervical cancer screening acceptability among adults in Quebec, Canada

BACKGROUND: The Pap test has been used for cervical cancer screening for more than four decades. A human papillomavirus (HPV) vaccine has been approved for use in Canada and is commercially available now. These two preventive interventions should be considered simultaneously. General population supp...

Descripción completa

Detalles Bibliográficos
Autores principales: Sauvageau, Chantal, Duval, Bernard, Gilca, Vladimir, Lavoie, France, Ouakki, Manale
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2206027/
https://www.ncbi.nlm.nih.gov/pubmed/17961209
http://dx.doi.org/10.1186/1471-2458-7-304
_version_ 1782148432479125504
author Sauvageau, Chantal
Duval, Bernard
Gilca, Vladimir
Lavoie, France
Ouakki, Manale
author_facet Sauvageau, Chantal
Duval, Bernard
Gilca, Vladimir
Lavoie, France
Ouakki, Manale
author_sort Sauvageau, Chantal
collection PubMed
description BACKGROUND: The Pap test has been used for cervical cancer screening for more than four decades. A human papillomavirus (HPV) vaccine has been approved for use in Canada and is commercially available now. These two preventive interventions should be considered simultaneously. General population support is an important factor for the successful combination of these interventions. The study had two objectives: 1) To assess practices, beliefs, and attitudes regarding Pap test screening and HPV immunization; 2) To identify socio-demographic factors for Pap screening and vaccine acceptability. METHODS: In 2006, 500 adults were invited to participate in a telephone survey in the region of Quebec City (urban and rural population, 600 000), Canada. Some neutral and standardized information on Pap test and HPV was provided before soliciting opinions. RESULTS: 471 adults (18–69 year-olds) answered the questionnaire, the mean age was 45 years, 67% were female, and 65% had college or university degree. Eighty-six percent of women had undergone at least one Pap-test in their life, 55% in the last year, and 15% from 1 to 3 years ago. Among screened women, the test had been performed in the last three years in 100% of 18–30 year-olds, but only in 67% of 60–69 year-olds (P < 0.0001). Only 15% of respondents had heard of HPV. Eighty-seven percent agreed that HPV vaccines could prevent cervical cancer, 73% that the vaccine has to be administered before the onset of sexual activity, 89% would recommend vaccination to their daughters and nieces. Among respondents < 25 years, 91% would agree to receive the vaccine if it is publicly funded, but only 72% would agree to pay $100/dose. CONCLUSION: There is an important heterogeneity in cervical cancer screening frequency and coverage. Despite low awareness of HPV infection, the majority of respondents would recommend or are ready to receive the HPV vaccine, but the cost could prevent its acceptability.
format Text
id pubmed-2206027
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-22060272008-01-18 Human Papilloma Virus vaccine and cervical cancer screening acceptability among adults in Quebec, Canada Sauvageau, Chantal Duval, Bernard Gilca, Vladimir Lavoie, France Ouakki, Manale BMC Public Health Research Article BACKGROUND: The Pap test has been used for cervical cancer screening for more than four decades. A human papillomavirus (HPV) vaccine has been approved for use in Canada and is commercially available now. These two preventive interventions should be considered simultaneously. General population support is an important factor for the successful combination of these interventions. The study had two objectives: 1) To assess practices, beliefs, and attitudes regarding Pap test screening and HPV immunization; 2) To identify socio-demographic factors for Pap screening and vaccine acceptability. METHODS: In 2006, 500 adults were invited to participate in a telephone survey in the region of Quebec City (urban and rural population, 600 000), Canada. Some neutral and standardized information on Pap test and HPV was provided before soliciting opinions. RESULTS: 471 adults (18–69 year-olds) answered the questionnaire, the mean age was 45 years, 67% were female, and 65% had college or university degree. Eighty-six percent of women had undergone at least one Pap-test in their life, 55% in the last year, and 15% from 1 to 3 years ago. Among screened women, the test had been performed in the last three years in 100% of 18–30 year-olds, but only in 67% of 60–69 year-olds (P < 0.0001). Only 15% of respondents had heard of HPV. Eighty-seven percent agreed that HPV vaccines could prevent cervical cancer, 73% that the vaccine has to be administered before the onset of sexual activity, 89% would recommend vaccination to their daughters and nieces. Among respondents < 25 years, 91% would agree to receive the vaccine if it is publicly funded, but only 72% would agree to pay $100/dose. CONCLUSION: There is an important heterogeneity in cervical cancer screening frequency and coverage. Despite low awareness of HPV infection, the majority of respondents would recommend or are ready to receive the HPV vaccine, but the cost could prevent its acceptability. BioMed Central 2007-10-25 /pmc/articles/PMC2206027/ /pubmed/17961209 http://dx.doi.org/10.1186/1471-2458-7-304 Text en Copyright © 2007 Sauvageau et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Sauvageau, Chantal
Duval, Bernard
Gilca, Vladimir
Lavoie, France
Ouakki, Manale
Human Papilloma Virus vaccine and cervical cancer screening acceptability among adults in Quebec, Canada
title Human Papilloma Virus vaccine and cervical cancer screening acceptability among adults in Quebec, Canada
title_full Human Papilloma Virus vaccine and cervical cancer screening acceptability among adults in Quebec, Canada
title_fullStr Human Papilloma Virus vaccine and cervical cancer screening acceptability among adults in Quebec, Canada
title_full_unstemmed Human Papilloma Virus vaccine and cervical cancer screening acceptability among adults in Quebec, Canada
title_short Human Papilloma Virus vaccine and cervical cancer screening acceptability among adults in Quebec, Canada
title_sort human papilloma virus vaccine and cervical cancer screening acceptability among adults in quebec, canada
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2206027/
https://www.ncbi.nlm.nih.gov/pubmed/17961209
http://dx.doi.org/10.1186/1471-2458-7-304
work_keys_str_mv AT sauvageauchantal humanpapillomavirusvaccineandcervicalcancerscreeningacceptabilityamongadultsinquebeccanada
AT duvalbernard humanpapillomavirusvaccineandcervicalcancerscreeningacceptabilityamongadultsinquebeccanada
AT gilcavladimir humanpapillomavirusvaccineandcervicalcancerscreeningacceptabilityamongadultsinquebeccanada
AT lavoiefrance humanpapillomavirusvaccineandcervicalcancerscreeningacceptabilityamongadultsinquebeccanada
AT ouakkimanale humanpapillomavirusvaccineandcervicalcancerscreeningacceptabilityamongadultsinquebeccanada